康泰生物(300601.SZ)：子公司荣获江苏省科技进步奖二等奖

Core Viewpoint - Kangtai Biological (300601.SZ) has achieved significant recognition in the field of technological innovation by winning the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2] Group 1: Project Recognition and Achievements - The project, led by the Jiangsu Provincial Center for Disease Control and Prevention, addresses critical challenges in the prevention and control of emerging viral infectious diseases [2] - Kangtai's subsidiary, Beijing Minhai Biotechnology Co., Ltd., has previously received the second prize of the Beijing Science and Technology Progress Award and has been approved for the establishment of a key laboratory in synthetic immunology and vaccine manufacturing [1] Group 2: Technological Innovations - The project includes a highly efficient response system developed through a series of technical breakthroughs, with Kangtai providing key technological support through its inactivated enterovirus vaccine platform [2] - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2] Group 3: Market Position and Future Prospects - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for Kangtai [2] - Successful development of these vaccines will enhance the company's multi-valent vaccine portfolio, strengthen its core competitiveness, and solidify its market position for sustainable growth [2]